DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,006,320 | -0.7% | 4,193 | +4.3% | 0.50% | -3.3% |
| Q1 2023 | $1,013,201 | +95756.3% | 4,020 | +0.9% | 0.52% | -25.7% |
| Q4 2022 | $1,057 | -99.9% | 3,984 | -1.5% | 0.70% | -20.4% |
| Q3 2022 | $1,044,000 | +1.1% | 4,043 | -0.8% | 0.88% | -6.0% |
| Q2 2022 | $1,033,000 | -16.7% | 4,077 | -3.5% | 0.94% | +93.2% |
| Q1 2022 | $1,240,000 | -16.6% | 4,226 | -6.5% | 0.49% | +11.5% |
| Q4 2021 | $1,487,000 | +10.0% | 4,521 | +1.8% | 0.44% | -7.6% |
| Q3 2021 | $1,352,000 | +23.0% | 4,441 | +8.5% | 0.47% | -2.9% |
| Q2 2021 | $1,099,000 | +25.6% | 4,094 | +5.3% | 0.49% | -71.9% |
| Q1 2021 | $875,000 | +12.6% | 3,887 | +11.1% | 1.73% | +244.8% |
| Q4 2020 | $777,000 | -48.5% | 3,500 | -17.7% | 0.50% | -15.5% |
| Q3 2020 | $1,508,000 | +143.6% | 4,254 | +21.5% | 0.59% | -25.3% |
| Q2 2020 | $619,000 | +27.9% | 3,500 | 0.0% | 0.80% | -15.2% |
| Q1 2020 | $484,000 | -9.9% | 3,500 | 0.0% | 0.94% | +82.8% |
| Q4 2019 | $537,000 | – | 3,500 | – | 0.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |